Navigation Links
Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
Date:4/30/2008

CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that its Vice President of Research, Johannes Fruehauf, MD, Ph.D., is slated to speak at the RNAi World Congress meeting in Boston. His presentation, "Treatment of Gastrointestinal Targets using RNA Interference," is scheduled for 4:25 pm on Friday, May 2, at the Hilton Boston Logan Airport. Dr. Fruehauf is co-inventor of Cequent's proprietary TransKingdom RNA interference (tkRNAi(TM)) technology, designed to solve one of the key challenges to RNAi therapeutics -- delivery of the RNAi into the cell.

Cequent's goal with its first clinical candidate is to prevent polyp formation in patients with a high risk of developing colon cancer. In his talk, Dr. Fruehauf will give an overview of the company's preclinical-development program for the therapeutic, presenting efficacy data in mouse models and data on a major monkey toxicology study currently under way. The latter is the first study evaluating the safety and efficacy of tkRNAi in a non-human primate model -- an important step for Cequent in the development of tkRNAi-based drugs for human disease. In addition, Dr. Fruehauf will introduce Cequent's programs for inflammatory bowel disease (IBD) and human Papilloma virus (HPV), which targets cervical cancer.

Dr. Fruehauf's participation in the RNAi World Congress follows Cequent presentations at two other high-profile conferences. In March, Dr. Fruehauf introduced tkRNAi and its application in cancer prevention targeting beta-catenin at the Keystone Symposium on RNAi, MicroRNA, and Non-Coding RNA in Whistler, British Columbia. Cequent's Associate Director of RNAi Research, Jens Harborth, Ph.D., also presented at the conference, discussing the company's unique algorithm of developing tkRNAi target sequences, which are active across species. This approach allows
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
2. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
5. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015  Holographic Optical Technologies of Augusta, ... medical imaging, is entering the world of consumer electronics ... April 20 th , 2015, the campaign will introduce ... and 22-inch displays will allow consumers to view fully ... In addition to the two displays, the company will ...
(Date:3/27/2015)... -- Victoria Vein & Surgery Clinic is the only clinic offering ... Victoria, Texas . The clinic specializes in ... treatments for a variety of medical and cosmetic conditions. High-end ... services for their patients. Since adding laser tattoo removal, Victoria ... residents get rid of their unwanted ink. ...
(Date:3/27/2015)... 27, 2015   Cypher Genomics, Inc., ... data showing that, compared to a panel of ... highly equivalent interpretations of whether certain genetic abnormalities ... in a fraction of the time. Cypher,s Mantis ... comprehensive genetic analysis in non-invasive prenatal testing (NIPT) ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
(Date:3/28/2015)... March 28, 2015 An article in ... which could prove critical to organizations that deal with ... critical aspect of data security, is worsening . ... security report, every major category out of the twelve ... testing. “With all the craziness that has gone on ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for multiple ... injuries, according to new research released today at the American ... , “Our findings indicate that a 10 inch increase in ... a history of injury, a 10 mile per hour increase ... a history of injury, and playing for more than one ...
(Date:3/28/2015)... How best to treat and recover ... orthopaedic medicine. While diagnostic hip injections are commonly performed ... etiology, research presented today at the American Orthopaedic Society ... that pain relief from this diagnostic injection may not ... “Our study looked to assess if the amount of ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Early surgery ... with Type V AC joint injuries, according to new ... today at the American Orthopaedic Society for Sports Medicine’s ... to duty faster when surgery was not performed. , ... 7 receiving surgical treatment and 17 receiving non-surgical therapy. ...
Breaking Medicine News(10 mins):Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2
... have the largest volume of surgical procedures does not necessarily ... the results of a new study in the February issue ... . The findings of studies that suggest the higher ... hospital, the better that hospital,s outcomes will be, has resulted ...
... diseases like Alzheimer,s and Parkinson,s are partly attributable to ... Institutet in Sweden now demonstrate in a paper published ... enzymes can prevent the inflammation and thus constitute a ... microglial cells the nerve system,s primary immune cells ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, March ... diabetes were able to get injections of a new insulin drug ... findings still need to be confirmed in another phase of research, ... it were approved for this use. But those caveats aside, ...
... colleagues at Case Western Reserve University School of Medicine have ... a universally fatal, degenerative brain disease for which there is ... and typically leads to death within a year of disease ... of PLoS ONE, a scientific journal produced by ...
... HealthDay Reporter , WEDNESDAY, March 9 (HealthDay News) ... kids, brains are developing an ability to help fight ... Over a three-year period, researchers from Oregon and California studied ... insight into the brain,s wiring during adolescence, finding the most ...
... WEDNESDAY, March 9 (HealthDay News) -- Stroke survivors recover ... involved in their exercise therapy, a new European study ... stroke survivors found that adding family-assisted exercise therapy to ... distance walked, and ability to perform activities of daily ...
Cached Medicine News:Health News:Referral to high-volume hospitals for operations fails to improve outcomes statewide 2Health News:New Drug May Trim Insulin Injections to Just 3 a Week 2Health News:Researchers identify new biomarker for Creutzfeldt-Jakob disease, the human form of mad cow disease 2Health News:Researchers identify new biomarker for Creutzfeldt-Jakob disease, the human form of mad cow disease 3Health News:As Peer Pressure Increases, So Does Brain's Ability to Resist It 2Health News:As Peer Pressure Increases, So Does Brain's Ability to Resist It 3Health News:Family Involvement Helps Stroke Patients With Rehab 2
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
The Acceava pregnancy urine dipstick test provides qualitative determination of human chorionic gonadatropin in urine for early detection of pregnancy....
... Nucleic Sample Preparation Platform provides flexible, automated ... platform can prepare up to 96 patient ... and one half-hours, and performs onboard quantitation ... 30 minutes each. Based on Beckman ...
The Acceava Trichomonas Rapid Test is an immunochromatographic assay that detects pathogen antigens directly from vaginal swabs. Results are rapid, occurring within approximately 10 minutes....
Medicine Products: